The Effect of Mesotherapy and Intra-articular Steroid Injection in Shoulder Pain

The Comparison O the Efficacy of Mesotherapy and Intra-articular Steroid Injection in Patients with Chronic Shoulder Pain

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06610032

Acronym

Mesotherapy

Enrollment

Registered

2024-09-24

Start date

2024-07-01

Completion date

2024-09-10

Last updated

2024-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Shoulder Pain

Keywords

Shoulder, Mesotherapy, Pain, Steroid Injection

Brief summary

Patients with chronic shoulder pain will be divided randomly into mesotherapy and intra-articular steroid injection groups. Pain severity, range of motion and functional impairment will evaluated before treatment, 30 minutes and 4 weeks after the injections.

Detailed description

The study will include 84 patients aged 18-75 who applied to physical medicine and rehabilitation out-patient clinic with chronic shoulder pain between May and July 2024. Patients will be randomly divided into two groups: a mesotherapy group and steroid injection group, using the closed-envelope method. In the first group, a total of 3 sessions of mesotherapy are applied to the shoulder areas of the patients, 7 days apart. A single-session intra-articular 20 mg triamcinolone hexacetonide injection will be administered for patients in group 2. Pain severity, range of motion and functional impairment will evaluated before treatment, 30 minutes and 4 weeks after the injections.

Interventions

PROCEDUREMesotherapy

A total of 3 sessions of mesotherapy will be applied to the shoulder area of the patients, 7 days apart in group 1.

PROCEDUREIntra-articular steroid injection

Single session intra-articular 20 mg triamcinolone hexacetonide injection will be applied for patients in group 2.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Ages 18-75 2. Having shoulder pain for 6 months 3. VAS (Visual Analog Scale) > 4 4. Patients who can receive verbal instructions and do not have cognitive deficits

Exclusion criteria

1. Physical therapy applied to the shoulder area in the last 3 months 2. Having had a shoulder joint injection in the last 3 months 3. History of previous upper extremity surgery 4. History of drug allergy 5. Use of anticoagulant drugs (warfarin, low molecular weight heparin), patients with coagulation disorder 6. History of malignancy 7. Psychiatric illness 8. A rheumatological diagnosis such as Polymyalgia Rheumatica, Rheumatoid Arthritis, Ankylosing Spondylitis 9. Kidney failure 10. Liver disease 11. Heart failure 12. Pregnancy 13. Presence of infection, wound, allergy, burn-like lesions in the application area

Design outcomes

Primary

Measure	Time frame	Description
VAS (Visual Analouge Scale)	Patients will be evaluated before treatment, 30 minutes and 4 weeks after the injections.	Pain Severity evaluation ((0 (no pain)-10 (unbearable pain))
Shoulder Disability Questionnaire' (OSS) form	Patients will be evaluated before treatment, 30 minutes and 4 weeks after the injections.	Functional Disability evaluation (0-100)
Goniometric shoulder range of motion	Patients will be evaluated before treatment, 30 minutes and 4 weeks after the injections.	shoulder range of motion evaluation

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026